Koyama Koichi, Okamura Terue, Kawabe Joji, Ozawa Nozomi, Torii Kenzi, Umesaki Naohiko, Miyama Masato, Ochi Hironobu, Yamada Ryusaku
Department of Radiology, Osaka City University School of Medicine, Osaka, Japan.
J Nucl Med. 2003 Mar;44(3):353-8.
The purpose of this study was to evaluate PET using (18)F-FDG for gynecologic lesions with continuous bladder irrigation to eliminate artifacts from the (18)F-FDG activity in the bladder.
Forty-one patients were studied. They had 23 cervical uterine lesions (15 cases of cancer, 5 recurrences, 3 nonrecurrences); 8 cases of uterine corpus cancer, including 2 recurrences; and 10 ovarian masses (6 malignant, 4 nonmalignant). All cases of cancer were histologically proven; however, 2 cases of nonrecurrent uterine cervical carcinomas were diagnosed by clinical course. Continuous bladder irrigation was performed 35-55 min after intravenous administration of 185-370 MBq (18)F-FDG, and an emission scan was obtained 40-55 min after intravenous administration. Standardized uptake value (SUV) was used to estimate the degree of (18)F-FDG uptake quantitatively.
After bladder irrigation, the (18)F-FDG activity in the urinary tract was eliminated in 33 patients, so that detection of tumor (18)F-FDG accumulation was easy. Two patients showed residual activity in the urinary bladder, and 6 patients showed activity in the ureter. An artifact was seen in 1 patient with residual activity in the urinary bladder caused by insufficient irrigation. However, these residual activities had no influence on detecting (18)F-FDG accumulation in tumor. The mean (+/-SD) of SUVs of malignant lesions was 6.04 +/- 3.22, that of nonmalignant lesions was 1.71 +/- 1.12, and the difference was significant (P = 0.0002). SUVs of all malignant lesions were greater than 2.0, and SUVs of all nonmalignant lesions, except the 1 case of ovarian fibroma, were less than 2.0.
(18)F-FDG PET with continuous bladder irrigation is useful for eliminating (18)F-FDG activity in the bladder and for differentiating between malignant and nonmalignant uterine or ovarian masses.
本研究的目的是评估使用(18)F-FDG的PET在持续膀胱冲洗的情况下对妇科病变的应用,以消除膀胱中(18)F-FDG活性产生的伪影。
对41例患者进行了研究。他们有23例宫颈子宫病变(15例癌症、5例复发、3例未复发);8例子宫体癌,包括2例复发;以及10例卵巢肿块(6例恶性、4例非恶性)。所有癌症病例均经组织学证实;然而,2例未复发的子宫颈癌是根据临床病程诊断的。在静脉注射185-370MBq(18)F-FDG后35-55分钟进行持续膀胱冲洗,并在静脉注射后40-55分钟进行发射扫描。使用标准化摄取值(SUV)定量估计(18)F-FDG摄取程度。
膀胱冲洗后,33例患者尿路中的(18)F-FDG活性被消除,从而易于检测肿瘤(18)F-FDG的积聚。2例患者膀胱中显示有残留活性,6例患者输尿管中有活性。1例膀胱有残留活性的患者因冲洗不足出现了伪影。然而,这些残留活性对检测肿瘤中(18)F-FDG的积聚没有影响。恶性病变的SUV平均值(±标准差)为6.04±3.22,非恶性病变为1.71±1.12,差异有统计学意义(P = 0.0002)。所有恶性病变的SUV均大于2.0,除1例卵巢纤维瘤外,所有非恶性病变的SUV均小于2.0。
持续膀胱冲洗的(18)F-FDG PET有助于消除膀胱中的(18)F-FDG活性,并有助于区分子宫或卵巢的恶性和非恶性肿块。